Conexeu Sciences is trading at $4.34, up +9.92% in pre-market; available coverage does not establish that the private placement caused the gain.
- On October 15, 2026, Conexeu Sciences announced it closed an approximately $5 million private placement led by existing shareholders, management and directors.
- Proceeds are intended for working capital, continued manufacturing scale-up, regulatory testing and preclinical work toward a planned FDA 510(k) submission in the first quarter of 2027.
- $250,000 of subscriptions remains escrowed pending stockholder approval.